Mona Motwani

3.0k total citations · 1 hit paper
32 papers, 1.8k citations indexed

About

Mona Motwani is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mona Motwani has authored 32 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 13 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mona Motwani's work include interferon and immune responses (4 papers), Cancer-related Molecular Pathways (4 papers) and Lung Cancer Research Studies (3 papers). Mona Motwani is often cited by papers focused on interferon and immune responses (4 papers), Cancer-related Molecular Pathways (4 papers) and Lung Cancer Research Studies (3 papers). Mona Motwani collaborates with scholars based in United States, France and China. Mona Motwani's co-authors include Katherine A. Fitzgerald, Gary K. Schwartz, Thomas Delohery, Ann Marshak‐Rothstein, Rakesh Kumar, Xiaoling Li, Sudesh Pawaria, Terry Fang, Linda C. Burkly and Ning Guo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Mona Motwani

31 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DNA sensing by the cGAS–STING pathway in health and disease

2019 1.0k citations Mona Motwani, Katherine A. Fitzgerald et al. Nature Reviews Genetics profile →

Peers

Countries citing papers authored by Mona Motwani

Since Specialization

Citations

This map shows the geographic impact of Mona Motwani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mona Motwani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mona Motwani more than expected).

Fields of papers citing papers by Mona Motwani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mona Motwani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mona Motwani. The network helps show where Mona Motwani may publish in the future.

Co-authorship network of co-authors of Mona Motwani

This figure shows the co-authorship network connecting the top 25 collaborators of Mona Motwani. A scholar is included among the top collaborators of Mona Motwani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mona Motwani. Mona Motwani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of Extended Dosing Intervals and Ipsilateral Versus Contralateral Boosting on mRNA Vaccine Immunogenicity in Mice 2025 ·Vaccines ·Bin Lu, Omkar Chaudhary, Balaji Banoth, (unknown), Wei Zong, (unknown), (unknown), Mona Motwani, (unknown), Donghui Zhang, (unknown), Bachra Rokbi, W. L. Warren, Frank DeRosa, Sudha Chivukula	1
2	Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system 2024 ·Molecular Therapy ·(unknown), (unknown), (unknown), (unknown), Feng Wang, (unknown), (unknown), Karen Kelly, Pranathi M. Krishnamurthy, Alexandra Weiss, Miklós Marosföi, R King, Mona Motwani, Heather Gray‐Edwards, Katherine A. Fitzgerald, Robert H. Brown, Jonathan K. Watts	9
3	Radioresistant cells initiate lymphocyte-dependent lung inflammation and IFNγ-dependent mortality in STING gain-of-function mice 2022 ·Proceedings of the National Academy of Sciences ·(unknown), Mona Motwani, (unknown), Ann Marshak‐Rothstein, Katherine A. Fitzgerald	19
4	cGAS-STING Pathway Does Not Promote Autoimmunity in Murine Models of SLE 2021 ·Frontiers in Immunology ·Mona Motwani, (unknown), (unknown), (unknown), Zhaozhao Jiang, Shruti Sharma, Gretchen A. Baltus, Kevin M. Nickerson, Ann Marshak‐Rothstein, Katherine A. Fitzgerald	48
5	P2.01-19 Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET+ Non-Small Cell Lung Cancer: Trial in Progress 2019 ·Journal of Thoracic Oncology ·Clara B. Ocampo, Jun Wu, Jyotirmoy Dey, Zhaowen Sun, Mona Motwani, (unknown), Apurvasena Parikh, Jennifer Hay, Philip Komarnitsky, Bruce Allen Bach	3
6	Hierarchy of clinical manifestations in SAVI N153S and V154M mouse models 2019 ·Proceedings of the National Academy of Sciences ·Mona Motwani, Sudesh Pawaria, (unknown), (unknown), (unknown), Terry Fang, Linda C. Burkly, Ann Marshak‐Rothstein, Katherine A. Fitzgerald	99
7	MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer 2019 ·Journal of Thoracic Oncology ·D. Ross Camidge, Fabrice Barlési, J M Goldman, Daniel Morgensztern, Rebecca S. Heist, Everett E. Vokes, Alexander I. Spira, Eric Angevin, Wu‐Chou Su, David S. Hong, John H. Strickler, Mona Motwani, Zhaowen Sun, Apurvasena Parikh, Philip Komarnitsky, Jun Wu, Karen Kelly	2
8	DNA sensing by the cGAS–STING pathway in health and disease breakdown → 2019 ·Nature Reviews Genetics ·Mona Motwani, (unknown), Katherine A. Fitzgerald	1045
9	Genetic Models Reveal cis and trans Immune-Regulatory Activities for lincRNA-Cox2 2018 ·Cell Reports ·Roland Elling, Elektra K. Robinson, (unknown), (unknown), Sergio Covarrubias, Sol Katzman, Abigail F. Groff, Zhaozhao Jiang, (unknown), Mona Motwani, Jennie Chan, Shruti Sharma, Elizabeth J. Hennessy, Garret A. FitzGerald, Michael T. McManus, John L. Rinn, Katherine A. Fitzgerald, Susan Carpenter	72
10	A phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy 2017 ·Annals of Oncology ·Philip Komarnitsky, HJ Lee, Manan Shah, S. Wong, (unknown), (unknown), (unknown), (unknown), Mona Motwani, (unknown)	4
11	Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells 2015 ·Oncogene ·David J. Gordon, Mona Motwani, David Pellman	13
12	Non-synonymous variations in cancer and their effects on the human proteome: workflow for NGS data biocuration and proteome-wide analysis of TCGA data 2014 ·BMC Bioinformatics ·Charles N. Cole, Konstantinos Krampis, Konstantinos Karagiannis, Jonas S. Almeida, William J. Faison, Mona Motwani, Quan Wan, (unknown), Yang Pan, Vahan Simonyan, Raja Mazumder	12
13	Identification of Novel Gene Targets and Functions of p21-Activated Kinase 1 during DNA Damage by Gene Expression Profiling 2013 ·PLoS ONE ·Mona Motwani, (unknown), Anélia Horvath, Rakesh Kumar	29
14	p21-activated Kinase-1 Signaling Regulates Transcription of Tissue Factor and Tissue Factor Pathway Inhibitor 2012 ·Journal of Biological Chemistry ·Beatriz Sánchez‐Solana, Mona Motwani, Da‐Qiang Li, Jeyanthy Eswaran, Rakesh Kumar	15
15	Proteome-Wide Analysis of Single-Nucleotide Variations in the N-Glycosylation Sequon of Human Genes 2012 ·PLoS ONE ·Raja Mazumder, (unknown), Mona Motwani, Sona Vasudevan, Radoslav Goldman	32
16	Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases 2011 ·Hepatology ·(unknown), Da‐Qiang Li, Aiwu Ruth He, Mona Motwani, Vasilis Vasiliou, Jeyanthy Eswaran, Lopa Mishra, Rakesh Kumar	34
17	Pharmacodynamics and pharmacokinetics of AUY922 in a phase I study of solid tumor patients 2009 ·Journal of Clinical Oncology ·Susan Ide, Mona Motwani, Michael Rugaard Jensen, (unknown), (unknown), Philipp Stiegler, (unknown), Cornelia Quadt	6
18	Effect of TKI258 on plasma biomarkers and pharmcokinetics in patients with advanced melanoma 2009 ·Journal of Clinical Oncology ·M. Shi, (unknown), Jason Chesney, (unknown), Mona Motwani, (unknown), Mesia Steed, Oezlem Anak, Graeme Jones, (unknown), John M. Kirkwood	5
19	Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells. 2000 ·PubMed ·Mona Motwani, Xiaoling Li, Gary K. Schwartz	40
20	Role of the transcription factor AP-1 in melanoma differentiation (review). 1998 ·International Journal of Oncology ·Dong‐Chul Kang, Mona Motwani, Paul B. Fisher	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact